Literature DB >> 16817843

Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.

Gil Y Melmed1, Andrew F Ippoliti, Konstantinos A Papadakis, Tram T Tran, Jaime L Birt, Susie K Lee, Robert W Frenck, Stephan R Targan, Eric A Vasiliauskas.   

Abstract

BACKGROUND: Patients with chronic, immune-mediated conditions such as inflammatory bowel disease (IBD) are often treated with long-term immunosuppressive therapies, potentially increasing their risk of developing an infection. Empiric data suggest that vaccines are underutilized in immunocompromised patients, despite published guidelines recommending their use. We aimed to assess exposure risk and immunization status among patients receiving care in an IBD specialty clinic.
METHODS: Patients completed a self-administered, pretested, structured questionnaire during a routine visit for the management of IBD. Survey questions related to medical and immunization histories, and exposures to known risk factors for influenza, pneumococcus, viral hepatitis, and varicella. Additionally, in a subgroup of patients who agreed to donate a sample of blood, immune status to hepatitis A (HAV), hepatitis B (HBV), and varicella was determined.
RESULTS: Two hundred four patients were asked to participate in the study; 169 completed surveys and comprised the study population. Mean age was 35 yr (range 13-75 yr). One hundred forty-six respondents (86%) reported current or prior use of immunosuppressive medications. Only 45% of respondents recalled tetanus immunization within the past 10 yr, 41 (28%) reported regularly receiving flu shots, and 13 (9%) reported having received pneumococcal vaccine. The most common reasons for nonimmunization with influenza included lack of awareness (49%) and concern for side effects (18%). Responses indicated that 75 (44%) patients were at risk for HBV but only 47 (28%) had been vaccinated against the infection; of patients with previous HBV vaccination, only three of nine (33%) had measurable antibodies against hepatitis B surface antigen.
CONCLUSIONS: Immunization against selected vaccine-preventable illnesses was uncommon in patients with IBD, despite the presence of significant risk factors. Efforts to improve immunization status among patients with IBD and other chronic, immune-mediated conditions are needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817843     DOI: 10.1111/j.1572-0241.2006.00646.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  102 in total

1.  Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls.

Authors:  Mustafa Erhan Altunöz; Ebubekir Senateş; Atakan Yeşil; Turan Calhan; Ayşe Oya Kurdaş Ovünç
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

2.  Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease.

Authors:  Sara Lewin; Fernando S Velayos
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-09

Review 3.  Quality of care in inflammatory bowel disease.

Authors:  Brijen Shah; Andrew Tinsley; Thomas Ullman
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 4.  Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptake.

Authors:  Annika M Hofstetter; Philip LaRussa; Susan L Rosenthal
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

Review 5.  Elderly patients and inflammatory bowel disease.

Authors:  Danielle Nimmons; Jimmy K Limdi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

6.  Anti-tumor necrosis factor therapy and influenza: keeping it in perspective.

Authors:  Matt Shale; Markus Czub; Gilaad G Kaplan; Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

Review 7.  Quality improvement in gastroenterology clinical practice.

Authors:  Rakhi Kheraj; Sumeet K Tewani; Gyanprakash Ketwaroo; Daniel A Leffler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

Review 8.  Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

Authors:  Pilar López-Serrano; Jose Lázaro Pérez-Calle; Maria Dolores Sánchez-Tembleque
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

Review 9.  Efficacy of the vaccination in inflammatory bowel disease.

Authors:  Elisa Carrera; Rebeca Manzano; Elena Garrido
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

10.  Immunization history of children with inflammatory bowel disease.

Authors:  Ing Shian Soon; Jennifer C C deBruyn; Iwona Wrobel
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.